Frutarom Health increases phytopharmaceutical capacity
Acquisition of Extrakt Chemie and site investments in people, equipment, manufacturing buildings and new offices increases company's position in Germany.
Frutarom Health BU reports it will strengthen focus on its phytopharmaceutical business in 2017. This follows the 2016 acquisition of Extrakt Chemie, in Stadhagen, near Hannover, Germany, and supports the rapid growth of its pure phytopharmaceutical line.
Frutarom Health plans to grow its Extrakt Chemie acquisition through globalization via Frutarom's international sales network. Frutarom has initiated investments in the site to increase production capacity and fulfill the market needs of the pharmaceutical industry. The company has implemented a third production shift, to be followed by an expansion of the site (including production and office areas) to establish Extrakt Chemie as Frutarom´s Pharma Competence Center.
"With the acquisition of Extrakt Chemie, plus the directed site investments in people, equipment, manufacturing buildings and new offices, and the new, combined team of highly experienced pharmaceutical experts, we feel Frutarom can bring significant value to the phytopharmaceuticals market," says Barbara Bradl, Business Manager Pharma of Frutarom BU Health. "Adding the legacy Extrakt Chemie portfolio to the already strong EFLApharm line of Frutarom Health products creates new market opportunities for all both the companies and consumers. Growing this business is a key element of the Business Unit Health strategy."
Frutarom's premium portfolio of phytopharmaceutical ingredients, known as EFLApharm, has been significantly extended by such strategic acquisitions in the past 2 years. All products under the umbrella of EFLApharm are pharma-grade herbal extracts, produced according to GMP guidelines, and offer an advanced market entity to our business partners. The botanical extracts are suitable as APIs for the global pharmaceutical market, and are supported by a dedicated Regulatory Affairs team that provides specialized pharma services. All EFLApharm herbal extracts carry a pharma-grade documentation package that covers the 3.2.S part. This documentation package is also known as Active Substance Master File (ASMF).
The GMP-certified production and the Pharma Competence Center of Extrakt Chemie are strategically located in Stadthagen, in the center of Germany-the heart of the global phytopharmaceutical market.
The global size of the phytopharmaceutical market is estimated at €750-850 million, with 90% of the market concentrated domestically in the EU. German-speaking countries make up half of that market, followed by France. The predominant health areas this market covers are cough & cold; mental health (stress, mood, fatigue, restlessness, cognition); gastrointestinal disorders; and cardiovascular health.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance